275 related articles for article (PubMed ID: 18631865)
1. mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
Letavernier E; Legendre C
Transplant Rev (Orlando); 2008 Apr; 22(2):125-30. PubMed ID: 18631865
[TBL] [Abstract][Full Text] [Related]
2. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
Diekmann F; Andrés A; Oppenheimer F
Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
[TBL] [Abstract][Full Text] [Related]
3. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
Ruiz JC; Campistol JM; Sánchez-Fructuoso A; Rivera C; Oliver J; Ramos D; Campos B; Arias M; Diekmann F
Nephrol Dial Transplant; 2006 Nov; 21(11):3252-7. PubMed ID: 16954170
[TBL] [Abstract][Full Text] [Related]
4. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
[TBL] [Abstract][Full Text] [Related]
5. Proteinuria in transplant patients associated with sirolimus.
Franco AF; Martini D; Abensur H; Noronha IL
Transplant Proc; 2007 Mar; 39(2):449-52. PubMed ID: 17362756
[TBL] [Abstract][Full Text] [Related]
6. High sirolimus levels may induce focal segmental glomerulosclerosis de novo.
Letavernier E; Bruneval P; Mandet C; Duong Van Huyen JP; Péraldi MN; Helal I; Noël LH; Legendre C
Clin J Am Soc Nephrol; 2007 Mar; 2(2):326-33. PubMed ID: 17699432
[TBL] [Abstract][Full Text] [Related]
7. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
8. Proteinuria after conversion to sirolimus in renal transplant recipients.
Sahin GM; Sahin S; Kantarci G; Ergin H
Transplant Proc; 2006 Dec; 38(10):3473-5. PubMed ID: 17175308
[TBL] [Abstract][Full Text] [Related]
9. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
Vogelbacher R; Wittmann S; Braun A; Daniel C; Hugo C
Transplantation; 2007 Dec; 84(11):1492-9. PubMed ID: 18091526
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus in renal transplantation.
Morath C; Arns W; Schwenger V; Mehrabi A; Fonouni H; Schmidt J; Zeier M
Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
[TBL] [Abstract][Full Text] [Related]
11. Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria.
Diekmann F; Budde K; Slowinski T; Oppenheimer F; Fritsche L; Neumayer HH; Campistol JM
Transpl Int; 2008 Feb; 21(2):152-5. PubMed ID: 18005087
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
13. Post-rapamycin proteinuria: incidence, evolution, and therapeutic handling at a single center.
Pinheiro HS; Amaro TA; Braga AM; Bastos MG
Transplant Proc; 2006 Dec; 38(10):3476-8. PubMed ID: 17175309
[TBL] [Abstract][Full Text] [Related]
14. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
Nashan B
Transpl Int; 2004 Jul; 17(6):279-85. PubMed ID: 15221123
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy.
Dittrich E; Schmaldienst S; Soleiman A; Hörl WH; Pohanka E
Transpl Int; 2004 May; 17(4):215-20. PubMed ID: 15112032
[TBL] [Abstract][Full Text] [Related]
16. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
Wali RK; Weir MR
Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
[TBL] [Abstract][Full Text] [Related]
17. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
Pediatr Transplant; 2006 Aug; 10(5):565-9. PubMed ID: 16856992
[TBL] [Abstract][Full Text] [Related]
18. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.
Rodríguez-Moreno A; Ridao N; García-Ledesma P; Calvo N; Pérez-Flores I; Marques M; Barrientos A; Sánchez-Fructuoso AI
Transplant Proc; 2009; 41(6):2163-5. PubMed ID: 19715862
[TBL] [Abstract][Full Text] [Related]
20. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
Kacar S; Gurkan A; Karaca C; Varılsuha C; Tilif S
Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
